Redhill Biopharma Ltd
RDHL1.200USD
0.000
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.55MMarktkapitalisierung
0.13KGV TTM
mehr Informationen über Redhill Biopharma Ltd Unternehmen
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Unternehmensinformationen
BörsenkürzelRDHL
Name des UnternehmensRedhill Biopharma Ltd
IPO-datumFeb 01, 2011
CEOMr. Dror Ben-Asher
Anzahl der mitarbeiter35
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 01
Addresse21 Ha'arba'a St.
StadtTEL AVIV-YAFO
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl6473921
Telefon97235413131
Websitehttps://www.redhillbio.com/
BörsenkürzelRDHL
IPO-datumFeb 01, 2011
CEOMr. Dror Ben-Asher
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Heights Capital Management, Inc.
3.05%
Citadel Advisors LLC
0.94%
Desjardins Securities Inc.
0.15%
GAMMA Investing LLC
0.09%
Rhumbline Advisers Ltd. Partnership
0.06%
Other
95.72%
Aktionäre
Aktionäre
Anteil
Heights Capital Management, Inc.
3.05%
Citadel Advisors LLC
0.94%
Desjardins Securities Inc.
0.15%
GAMMA Investing LLC
0.09%
Rhumbline Advisers Ltd. Partnership
0.06%
Other
95.72%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
3.11%
Hedge Fund
0.94%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.09%
Other
95.70%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
39
98.72K
4.30%
-26.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
2023Q2
113
26.79K
29.96%
+840.00
2023Q1
122
24.63K
29.02%
+7.31K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Heights Capital Management, Inc.
70.00K
3.05%
+70.00K
--
Jan 25, 2024
Citadel Advisors LLC
21.51K
0.94%
+21.51K
--
Mar 31, 2025
Desjardins Securities Inc.
3.39K
0.15%
--
--
Mar 31, 2025
GAMMA Investing LLC
3.57K
0.16%
-1.52K
-29.89%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.39K
0.06%
+190.00
+15.86%
Mar 31, 2025
BofA Global Research (US)
303.00
0.01%
+301.00
+15050.00%
Mar 31, 2025
Group One Trading, L.P.
22.00
0%
--
--
Mar 31, 2025
Yorkville Asset Management, Inc.
14.00
0%
--
--
Sep 30, 2024
Morgan Stanley & Co. LLC
11.00
0%
-2.20K
-99.50%
Mar 31, 2025
FMP Wealth Advisers
47.00
0%
+47.00
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
Datum
Art
Verhältnis
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
